Simultaneous NF-κB inhibition and E-cadherin upregulation mediate mutually synergistic anticancer activity of celastrol and SAHAin vitroandin vivo-Reference-Cited by-同舟云学术

Simultaneous NF-κB inhibition and E-cadherin upregulation mediate mutually synergistic anticancer activity of celastrol and SAHAin vitroandin vivo

Published:2014-03-07 Issue:7 Volume:135 Page:1721-1732
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Zheng Lin¹,Fu Yingying¹,Zhuang Linhan¹,Gai Renhua¹,Ma Jian¹,Lou Jianshu¹,Zhu Hong¹,He Qiaojun¹,Yang Bo¹

Affiliation:

1. Zhejiang Province Key Laboratory of Anti-Cancer Drug Research; Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University; Hangzhou China

Funder

National Natural Science Foundation of China

Program for New Century Excellent Talents in University (NCET)

Zhejiang Provincial Program for the Cultivation of High-level Innovative Health talents.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference50 articles.

1. Histone deacetylase inhibitors: potential in cancer therapy;Marks;J Cell Biochem,2009

2. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma;Mann;Oncologist,2007

3. Targeting histone deacetylases: development of vorinostat for the treatment of cancer;Richon;Epigenomics,2010

4. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer;Blumenschein;Invest New Drugs,2008

5. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study;Modesitt;Gynecol Oncol,2008

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Celastrol as an intestinal FXR inhibitor triggers tripolide-induced intestinal bleeding: Underlying mechanism of gastrointestinal injury induced by Tripterygium wilfordii;Phytomedicine;2023-12

2. Celastrol inhibits lung cancer growth by triggering histone acetylation and acting synergically with HDAC inhibitors;Pharmacological Research;2022-11

3. Celastrol inhibits LL37-induced rosacea by inhibiting Ca2+/CaMKII-mTOR-NF-κB activation;Biomedicine & Pharmacotherapy;2022-09

4. SHP2 inhibition improves celastrol-induced growth suppression of colorectal cancer;Frontiers in Pharmacology;2022-09-01

5. CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling;BMC Cancer;2022-04-19